From Name:
From Email:
To Name:
To Email:

Optional Message:

Actelion wins crucial FDA approval for next-gen lung disease drug Opsumit

from FierceBiotech

The FDA came through with an approval for Actelion's pulmonary arterial hypertension drug Opsumit, its next-gen successor to the franchise drug Tracleer. And the Swiss company's shares shot up 7 percent on the news. The approval comes as no great surprise. The company had been steadily doing the rounds with regulators, armed with positive late-stage data. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063